Immunitybio (IBRX) had the highest return in January 2026 by a mid-cap US stock, returning 209.4%.

ASSET	MONTH	% RETURN
Immunitybio (IBRX)	January 2026	209.41%
Erasca (ERAS)	January 2026	183.29%
Alumis (ALMS)	January 2026	150.87%
USA Rare Earth (USAR)	January 2026	82.57%
Enliven Therapeutics (ELVN)	January 2026	70.65%
Ultra Clean (UCTT)	January 2026	67.1%
Ichor (ICHR)	January 2026	58.1%
Energy Fuels (UUUU)	January 2026	53.07%
Hycroft Mining (HYMC)	January 2026	52.29%
Fluence Energy (FLNC)	January 2026	51.13%
Redwire (RDW)	January 2026	48.36%
Babcock & Wilcox Enterprises (BW)	January 2026	48.31%
Amprius Technologies (AMPX)	January 2026	47.22%
Denison Mines (DNN)	January 2026	44.53%
Uranium Energy (UEC)	January 2026	44.27%
First Majestic Silver (AG)	January 2026	42.39%
Telephone and Data Systems (TDS)	January 2026	42.09%
Acm Research (ACMR)	January 2026	41.76%
Brookdale Senior Living (BKD)	January 2026	39.93%
Karman (KRMN)	January 2026	39.84%
Astronics (ATRO)	January 2026	39.22%
Allegro Microsystems (ALGM)	January 2026	36.7%
Figure Technology Solutions, Inc Class A Common Stock (FIGR)	January 2026	36.27%
Vishay Intertechnology (VSH)	January 2026	35.87%
Plexus (PLXS)	January 2026	35.39%

Mid-cap stocks are treated as having a market cap between $2B and $10B.